CN110204607B - 一种抗Mrgprx2抗体的优势抗原表位多肽及其应用 - Google Patents
一种抗Mrgprx2抗体的优势抗原表位多肽及其应用 Download PDFInfo
- Publication number
- CN110204607B CN110204607B CN201910469478.1A CN201910469478A CN110204607B CN 110204607 B CN110204607 B CN 110204607B CN 201910469478 A CN201910469478 A CN 201910469478A CN 110204607 B CN110204607 B CN 110204607B
- Authority
- CN
- China
- Prior art keywords
- antibody
- polypeptide
- mrgprx
- antigen
- epitope polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 55
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 52
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 51
- 102000036639 antigens Human genes 0.000 title claims abstract description 24
- 108091007433 antigens Proteins 0.000 title claims abstract description 24
- 239000000427 antigen Substances 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 33
- 101001029072 Homo sapiens Mas-related G-protein coupled receptor member X2 Proteins 0.000 claims abstract description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 18
- 238000001514 detection method Methods 0.000 claims abstract description 18
- 239000011248 coating agent Substances 0.000 claims description 15
- 238000000576 coating method Methods 0.000 claims description 15
- 238000002965 ELISA Methods 0.000 claims description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000003118 sandwich ELISA Methods 0.000 claims description 6
- 241001529936 Murinae Species 0.000 claims description 5
- 102000048835 human MRGPRX2 Human genes 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102100037125 Mas-related G-protein coupled receptor member X2 Human genes 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 10
- 229940126619 mouse monoclonal antibody Drugs 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000007788 liquid Substances 0.000 abstract description 8
- 238000012216 screening Methods 0.000 abstract description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000007790 solid phase Substances 0.000 abstract description 3
- 238000003766 bioinformatics method Methods 0.000 abstract description 2
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- 238000005406 washing Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 14
- 208000003455 anaphylaxis Diseases 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 206010020751 Hypersensitivity Diseases 0.000 description 10
- 239000006180 TBST buffer Substances 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 206010002216 Anaphylactoid reaction Diseases 0.000 description 7
- 210000003630 histaminocyte Anatomy 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 239000012224 working solution Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002052 anaphylactic effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 1
- JPVGHHQGKPQYIL-KBPBESRZSA-N Gly-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 JPVGHHQGKPQYIL-KBPBESRZSA-N 0.000 description 1
- RZEDHGORCKRINR-STQMWFEESA-N Gly-Trp-Cys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN RZEDHGORCKRINR-STQMWFEESA-N 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- JPYPRVHMKRFTAT-KKUMJFAQSA-N Lys-Phe-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N JPYPRVHMKRFTAT-KKUMJFAQSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- XDMMOISUAHXXFD-SRVKXCTJSA-N Phe-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O XDMMOISUAHXXFD-SRVKXCTJSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- WYLAVUAWOUVUCA-XVSYOHENSA-N Thr-Phe-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O WYLAVUAWOUVUCA-XVSYOHENSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000024829 digestive system symptom Diseases 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- -1 inflammatory factors Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910469478.1A CN110204607B (zh) | 2019-05-31 | 2019-05-31 | 一种抗Mrgprx2抗体的优势抗原表位多肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910469478.1A CN110204607B (zh) | 2019-05-31 | 2019-05-31 | 一种抗Mrgprx2抗体的优势抗原表位多肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110204607A CN110204607A (zh) | 2019-09-06 |
CN110204607B true CN110204607B (zh) | 2021-04-20 |
Family
ID=67789971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910469478.1A Active CN110204607B (zh) | 2019-05-31 | 2019-05-31 | 一种抗Mrgprx2抗体的优势抗原表位多肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110204607B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106754731A (zh) * | 2017-02-23 | 2017-05-31 | 西安交通大学 | MrgprX2高表达的重组细胞及MrgprX2高表达膜受体固定相及制备方法和应用 |
CN107703312A (zh) * | 2017-11-15 | 2018-02-16 | 西安交通大学 | 筛查药物类过敏反应敏感人群的蛋白标记物和方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1340979A3 (en) * | 2002-02-27 | 2004-02-04 | Pfizer Limited | Neuropeptide receptor and uses thereof |
WO2004000999A2 (en) * | 2002-06-21 | 2003-12-31 | California Institute Of Technology | Identification of a receptor controlling migration and metastasis of skin cancer cells |
EP3174987B1 (en) * | 2014-08-01 | 2023-10-11 | The Johns Hopkins University | Mrgprx2/mrgprb2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions |
CN107142325A (zh) * | 2017-06-28 | 2017-09-08 | 西安交通大学 | 一种用于药物类过敏反应敏感人群筛查的基因标志物及其应用 |
-
2019
- 2019-05-31 CN CN201910469478.1A patent/CN110204607B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106754731A (zh) * | 2017-02-23 | 2017-05-31 | 西安交通大学 | MrgprX2高表达的重组细胞及MrgprX2高表达膜受体固定相及制备方法和应用 |
CN107703312A (zh) * | 2017-11-15 | 2018-02-16 | 西安交通大学 | 筛查药物类过敏反应敏感人群的蛋白标记物和方法 |
Non-Patent Citations (1)
Title |
---|
MRGPRX2 is essential for sinomenine hydrochloride induced anaphylactoid reactions;Rui Liu等;《Biochemical Pharmacology》;20171004;第146卷;第214-223页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110204607A (zh) | 2019-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2458378B1 (en) | Insulin measurement method | |
CN101949935A (zh) | He4单抗、多抗制备及相关诊断试剂盒研制 | |
CN110229228B (zh) | 一种对类过敏反应特异性受体mrgprx2蛋白的具有免疫原性的多肽及其应用 | |
CN105606814B (zh) | 检测人ApoE‑ε4蛋白的荧光免疫层析试纸及其制备方法 | |
CN110240643B (zh) | 一种用于制备类过敏反应的双抗夹心试剂盒配对抗体的多肽及其应用 | |
CA2785678C (en) | Human insulin assay and assay reagent | |
CN107478848B (zh) | 定量检测人NT-proBNP的试剂盒及其制备方法 | |
CN104418937B (zh) | 人pgii抗原表位肽、抗原、抗体、用途及试剂盒 | |
CN110204607B (zh) | 一种抗Mrgprx2抗体的优势抗原表位多肽及其应用 | |
CN112986586A (zh) | 一种氨基末端脑尿钠肽检测方法和试剂盒 | |
CN109503713A (zh) | 抗人saa单克隆抗体及其制备方法和应用 | |
CN110352351B (zh) | 使用抗人bnp片段(4-32)抗体的免疫测定方法 | |
CN113832132B (zh) | 一种烙铁头svmp蛋白特异性短肽、抗烙铁头svmp蛋白抗体和蛇伤检测试剂盒 | |
CN107446040B (zh) | 人st2抗原表位肽、抗原、抗体、试剂盒及应用 | |
CN106220722B (zh) | Dkk1自身抗体识别的抗原多肽及其用途 | |
CN110204606B (zh) | 一种用于制备兔多克隆抗体的多肽及其应用 | |
CN110229227B (zh) | 一种用于制备elisa鼠单克隆包被抗体和兔多克隆检测抗体的多肽及其应用 | |
CN107746430A (zh) | 一种gp73 c端抗原的制备及其应用 | |
CN107002065A (zh) | 对TRACP‑5b(酒石酸抵抗性酸性磷酸酶5b)具有特异性的蛋白定量法 | |
CN105669835B (zh) | 人ApoE-ε4抗原表位肽、抗原、抗体、应用及试剂盒 | |
CN105652011B (zh) | 检测人HSP90α‑2蛋白的荧光免疫层析试纸及其制备方法 | |
JP7266252B2 (ja) | 新規の免疫グロブリンeのエピトープ、それと結合する抗体および前記抗体を含む試料のうち免疫グロブリンeを分析するためのキット | |
CN112725286B (zh) | 一种分泌雷公藤甲素单克隆抗体的杂交瘤细胞株及其应用 | |
CN110054663B (zh) | Ckap4抗原表位肽、抗原、单克隆抗体及其应用和ckap4检测试纸条 | |
KR20080028642A (ko) | 유방암 진단용 단백질 마커 엔도레펠린 lg3 절편 및 이에대한 항체를 포함하는 유방암 진단키트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220713 Address after: 710000 building 7, fengyeyuan North District, Yanta District, Xi'an City, Shaanxi Province Patentee after: Yu Xiangdong Address before: 710000 room 304, 3 / F, building 7, laianyihun, No. 6 Dazhai Road, Lianhu District, Xi'an City, Shaanxi Province Patentee before: Shaanxi Tianyi Biotechnology Co.,Ltd. Effective date of registration: 20220713 Address after: 710000 room 304, 3 / F, building 7, laianyihun, No. 6 Dazhai Road, Lianhu District, Xi'an City, Shaanxi Province Patentee after: Shaanxi Tianyi Biotechnology Co.,Ltd. Address before: 710049 No. 28 West Xianning Road, Shaanxi, Xi'an Patentee before: XI'AN JIAOTONG University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231208 Address after: Room 404, Building 8, West Life Science Park, Intersection of Keyuan Fourth Road and Fengdong Avenue, Fengdong New City, Xi'an City, Shaanxi Province, 710086 Patentee after: Shaanxi Tianyi Biotechnology Co.,Ltd. Address before: 710000 building 7, fengyeyuan North District, Yanta District, Xi'an City, Shaanxi Province Patentee before: Yu Xiangdong |
|
TR01 | Transfer of patent right |